...the Stanford Microbiome Therapies Initiative and co-founder of Revolution Medicines Inc....

...tumor indications: JAB-3068 and JAB-3312 from Beijing Jacobio Pharmaceutical Co. Ltd.; RMC-4630 from Sanofi (Euronext:SAN; NASDAQ:SNY) and Revolution Medicines Inc....

...Inc Pliant Therapeutics Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam...

...the next 18 months including a SHP-2 inhibitor brought in through a 2018 deal with Revolution Medicines Inc....

...investors’ demand for the cancer company’s shares rose both before and after its offering priced. Revolution Medicines Inc....
...held 21.7% of Revolution’s shares after the pricing. Third Rock had invested $31 million across Revolution Medicines’...
...the seven companies to list on NASDAQ this year via offerings larger than $25 million, Revolution Medicines’...

...other biotechs are aiming to price NASDAQ IPOs in the coming weeks, including cancer company Revolution Medicines Inc....

...Rock, Reid was CEO of Warp Drive Bio Inc., which the firm launched in 2012. Revolution Medicines Inc....

...Therapies” ). Revolution proposes NASDAQ listing After raising $100 million in a July series C, Revolution Medicines Inc....
...homology protein tyrosine phosphatase 2; mTOR (FRAP; RAFT1) - Mammalian target of rapamycin Hongjiang Li, Staff Writer Revolution Medicines Inc. Genmab...

...that change a target’s shape. Other companies seeking to drug allosteric sites on proteins include Revolution Medicines Inc....

...KRAS program Amgen Inc. (NASDAQ:AMGN) will test its KRAS inhibitor AMG 510 in combination with Revolution Medicines Inc.’s...
...Eaton, Staff Writer Talicia (RHB-105, heliconda) AMG 510 Fotivda, tivozanib (ASP4130, AV-951, krn951) RedHill Biopharma Ltd. Turning Point Therapeutics Inc. Amgen Inc. Revolution Medicines Inc. Aveo...